Skip to main content
. 2021 Sep 21;11(19):9538–9556. doi: 10.7150/thno.55954

Table 2.

Overview of the analytical performances of the major chemosensitivity assays described in the literature against a large array of solid cancers

Assay Cancer Success rate Accuracy PPV NPV Cohort size (number of patients) Sensitivity Specificity Authors References
ATP Gastrointestinal 85.0% 84.0% - - 25 64.0% 100.0% Kawamura et al., 1997 41
ATP Ovary 89.0% 71.0% 66.0% 89.0% 93 95.0% 44.0% Konecny et al., 2000 42
ATP Ovary 85.0% 85.0% 50.0% 100.0% 33 100.0% 82.0% Ng TY et al., 2000 43
ATP Ovary - 70.7% 83.0% 56.5% 161 68.8% 74.3% O'Meara et al., 2001 44
ATP Lung 90.6% 90.0% 100.0% 80.0% 31 83.3% 100.0% Kim BS et al., 2004 45
ATP Lung 90.6% - - - 53 - - Kang et al., 2005 22
ATP Lung 43.8% 68.8% 61.1% 78.6% 34 - - Moon YW et al., 2007 46
ATP Breast 93.0% 85.0% 100.0% 66.7% 43 78.6% 100.0% Kim et al., 2008 47
ATP Ovary 69.0% 90.0% 94.1% - 29 94.1% - Han et al., 2008 48
ATP Gastrointestinal 95.8% 77.8% 85.7% 75.9% 36 46.2% 95.7% Kim JH et al., 2010 49
ATP Colon 79.0% - 94.0% 38.0% 62 - - Lee et al., 2011 50
ATP Bladder 96.3% 74.3% 83.7% 66.7% 54 97.6% 20.0% Ge et al., 2012 51
ATP Ovary - - 83.0% 84.8% 80 88.6% 77.8% Zhang et al., 2015 52
HDRA Head and Neck 88.0% 74.0% 83.0% 64.0% 26 71.0% 78.0% Robbins et al., 1994 53
HDRA Gastric & Colon 96.3% - 66.7% 100.0% 38 100.0% 90.6% Furukawa et al., 1995 54
HDRA Ovary 97.0% 87.0% 88.0% 86.0% 15 88.0% 86.0% Ohie et al., 2000 55
HDRA Breast 98.8% 80.0% 100.0% 70.0% 15 62.5% 100.0% Tanino H et al., 2001 56
HDRA Head and Neck 97.6% - - - 42 - - Singh et al., 2002 57
HDRA Head and Neck - 91.7% 90.0% 100.0% 19 79.0% 66.7% Ariyoshi et al., 2003 58
HDRA Head and neck - 77.8% 76.9% 80.0% 49 90.9% 57.1% Hasegawa et al., 2007 59
HDRA Head and Neck 91.0% 74.0% 69.0% 80.0% 57 79.0% 71.0% Pathak et al., 2007 60
HDRA Lung 97.4% 83.0% 73.2% 100.0% 343 100.0% 68.1% Yoshimasu et al., 2007 61
HDRA Ovary - - 62.0% 81.0% 61 90.0% 43.0% Neubauer et al., 2008 62
HDRA Oesophagus 89.3% - - - 53 66.7% 55.6%-66.7% Fujita et al., 2009 63
HDRA Glioma 94.0% - - - 33 100.0% 60.0% Gwak H et al., 2011 64
HDRA Colon - 66.3% - - 86 72.7% 54.7% Yoon et al., 2012 65
ITRA Colon - 61.9% 57.1% 64.3% 42 44.4% 75.0% Yoon et al., 2017 24
ITRA Ovary - 44.4% 40.0% 66.7% 18 85.7% 18.2% Kim et al., 2019 25
CD-DST Multiple 80.0% 91.0% 80.0% 100.0% 11 100.0% 86.0% Kobayashi et al., 1997 66
CD-DST Breast 84.3% 87-94.4% 83.3% 95.5-100% 70 92.9% 62.5-95.5% Takamura et al., 2002 67
CD-DST Mesothelioma - 50.0% - - 26 100.0% 36.0% Higashiyama et al., 2008 68
CD-DST NSCLC - 70.0% 50.0% 92.0% 81 88.0% 63.0% Higashiyama et al., 2010 69
CD-DST Gastric 80.0% - - - 64 - - Naitoh et al., 2014 70
CD-DST OSCC 81.8% 92.3% 90.9% 100.0% 14 - - Sakuma et al., 2017 71
FCA Multiple - - 85.0% 97.0% 73 98.0% 81.0% Leone et al., 1991 27
The Oncogramme® Colorectal 97.4% 63.6% 64.7% 60.0% 19 84.6% 33.3% Bounaix Morand du Puch et al., 2016 39
CANScript™ Multiple - - 93.9% 100.0% 55 - - Majumder et al., 2015 37
ChemoFX® Ovary - - 63.6% 100.0% 18 - - Ness et al., 2002 72
ChemoFX® Breast 83.9% - - - 62 - - Mi et al., 2008 73
ChemoFX® Head and Neck 72.7% - 81.8% - 22 - - Jamal et al., 2017 74
ChemoID® Glioblastoma - - 54.6% 100.0% 11 100.0% 50.0% Claudio et al., 2017 75
MICK Endometrium 78.9% - - - 19 - - Ballard et al., 2010 32
Mean 86.6% 76.1% 76.7% 82.0% 51.8 84.2% 68.3%
Median 89.2% 77.8% 82.4% 81.0% 40.0 88.0% 72.7%